Development of a New Isogenic Cell-Xenograft System for Evaluation of NAD(P)H:Quinone Oxidoreductase-Directed Antitumor Quinones: Evaluation of the Activity of RH1

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 3147-3155

  Dehn, Donna L ^a   Winski, Shannon L ^a   Ross, David ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DIAZIRIDINYL 3 (HYDROXYMETHYL) 6 METHYL 1,4 BENZOQUINONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; CYTOCHROME B5 REDUCTASE; CYTOCHROME P450 REDUCTASE; DNA; MENADIONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE); RUFOCROMOMYCIN; SUPEROXIDE DISMUTASE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; DNA POLYMORPHISM; DRUG ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; AZIRIDINES; BENZOQUINONES; CELL DIVISION; CELL LINE, TUMOR; CISPLATIN; COMET ASSAY; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOBLOTTING; MICE; MICE, NUDE; NAD(P)H DEHYDROGENASE (QUINONE); TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME; WEIGHT LOSS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 2442484645     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0411     Document Type: Article

References (45)

1. Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990;50: 7483-9.
2. Siegel D, Gibson NW, Preusch PC, Ross D. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induce DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990;50:7293-300.
3. Beall H, Murphy A, Siegel D, Hargreaves R, Butler J, Ross D. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 1995;48:499-504.
4. Beall HD, Winski S, Swann E, et al. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity. J Med Chem 1998;41:4755-66.
5. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst (Bethesda) 1996;88:259-69.
6. Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T, Tsuruo T. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res 1996;56: 2823-6.
7. Traver RD, Horikoshi T, Danenberg KD, et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992;52:797-802.
8. Traver RD, Siegel D, Beall HD, et al. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br J Cancer 1997;75:69-75.
9. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:Quinone oxidoreductase 1. Mol Pharmcol 2001;59:263-8.
10. Winski SL, Hargreaves RH, Butler J, Ross D. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin Cancer Res 1998;4(12):3083-8.
11. Sharp SY, Kelland LR, Valenti MR, Burunton LA, Hobbs S, Workman P. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 2000;58:1146-55.
12. Collard J, Matthew AM, Double JA, Bibby MC. EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer 1995;71:1199-203.
13. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 1999;9:113-21.
14. Ernster L. DT-diaphorase Methods Enzymol 1967;10:309-17.
15. Benson AM, Hunkeler MJ, Talalay P. Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci USA 1980;77: 5216-20.
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein determination with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
17. Vermilion JL, Coon MJ. Purified liver microsomal NADPH-cytochrome P-450 reductase. Spectral characterization of oxidation-reduction states. J Biol Chem 1978;253(8):2694-704.
18. Mihara K, Sato R. Detergent-solubilized NADH-cytochrome b5 reductase. Methods Enzymol 1978;52:102-8.
19. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968;25(1):192-205.
20. Winski SL, Swann E, Hargreaves RH, et al. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem Pharmacol 2001;61(12):1509-16.
21. Ward TH, Butler J, Shahbakhti H, Richards JT. Comet assay studies on the activation of two diaziridinylbenzoquinones in K562 cells. Biochem Pharmacol 1967;53:1115-21.
22. Collins A, Dusinska M, Franklin M, et al. Comet assay in human biomonitoring studies: reliability, validation and applications. Environ Mol Mutagen 1997;30:139-46.
23. Lebailly P, Vigreux C, Godard T, et al. Assessment of DNA damage induced in vitro by etoposide and two fungicides (carbendazim and chlorothalonil) in human lymphocytes with the comet assay. Mutat Res 1997;375:205-17.
24. Kamer I, Rinkevich B. In vitro application of the comet assay for aquatic genotoxicity: considering a primary culture versus a cell line. Toxicol in Vitro 2002;12:177-84.
25. Patel V, Senderowicz AM, Pinto D Jr, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Investig 1998;102(9):1674-81.
26. Kruczynski A, Astruc J, Ricome C, Colpaert F, Hill BT. Definite antitumor activity of vinflunine, a novel fluorinated vinca alkaloid, against human tumour xenografts. In: Fiebig HH, Burger AM, editors. Relevance of tumor models for anticancer drug development. Contributions oncology, vol. 54. Basel: Karger; 1999. p. 369-78.
27. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer (Phila.) 1961;14:1272-94.
28. Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 2002;87:825-33.
29. Tice RR, Agurell E, Anderson D, et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000;35:206-21.
30. Beall HD, Liu Y, Siegel D, Bolton EM, Gibson NW, Ross D. Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem Pharmacol 1996;51(5):645-52.
31. Ross D, Beall H, Traver RD, Siegel D, Phillips RM, Gibson NW. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res 1994;6:493-500.
32. Paull K, Camalier R, Fitzsimmons SA, Lewis AD, Workman P, Grever M. Correlations of DT-diaphorase expression with cell sensitivity data obtained from the NCI human tumor cell line panel [abstract]. Proc Am Assoc Cancer Res 1994;35:369.
33. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:quinone oxidoreductase activity is the principal determinant of b-lapachone cytotoxicity. J Biol Chem 2000; 275:5416-24.
34. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8(1):221-32.
35. Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H: quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol 1991;42(5):1021-7.
36. Jarrett CM, Bibby MC, Phillips RM. Bioreductive enzymology of malignant and normal human tissues [abstract]. Proc Am Assoc Cancer Res 1998;39:429.
37. Ross D, Beall HD, Siegel D, Traver RD, Gustafson DL. Enzymology of bioreductive drug activation. Br J Cancer 1996;74:S1-8.
38. Stratford U, Workman P. Bioreductive drugs into the next millennium. Anti-Cancer Drug Des 1998;13:519-28.
39. Bolzan AD, Bianchi MS. Genotoxicity of streptonigrin: a review. Mutation Res 2001;488:25-37.
40. Paull K, Camalier R, Fitzsimmons SA, Lewis AD, Workman P, Grever M. Correlations of DT-diaphorase expression with cell sensitivity data obtained from the NCI human tumor cell line panel [abstract]]. Proc Am Assoc Cancer Res 1994;35:369.
41. Gustafson DL, Beall HD, Bolton EM, Ross D, Waldren CA. Expression of human NAD(P)H:quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones. Mol Pharmacol 1996;50:728-35.
42. Hargreaves RHJ, O'Hare CC, Hartley JA, Ross D, Butler J. Cross-linking and sequence specific alkylation of DNA by aziridinylquinones. 3. Effects of alkyl substituents. J Med Chem 1999;42:2245-50.
43. Roth T, Burger AM, Dengler W, Willmann H, Fiebig HH. Human tumor cell lines demonstrating the characteristics of patient tumors as useful models for anticancer drug screening. In: Fiebig HH, Burger AM, editors. Relevance of tumor models for anticancer drug development. Contribution oncology, vol. 54. Basel: Karger; 1999. p. 145-56.
44. Phillips RM, Burger AM, Fiebig H-H, Double JA. Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo. Biochem Pharmacol 2001;62:1371-7.
45. Faig M, Bianchet MA, Winski S, et al. Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones. Structure 2001;9:659-67.